Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T10430 eye drops for control of paediatric myopia progression
2025-521563-13-01Phase 2Authorised
- Sponsor
- Laboratoires Théa
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, single-arm trial of sodium phenylbutyrate in myopia, sponsored by Laboratoires Théa. Primary endpoint: Ocular treatment-emergent adverse events. Planned start Jun 2026; status: authorised.
02
Drugs
sodium phenylbutyrate
03
Conditions
myopia
Beyond the preview
Go deeper on 2025-521563-13-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521563-13-01.